<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089179</url>
  </required_header>
  <id_info>
    <org_study_id>PK-07- 017</org_study_id>
    <nct_id>NCT01089179</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions</brief_title>
  <official_title>An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 500 mg Tablet (Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single- Dose
      Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet (Test
      formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 500 mg Tablet
      (Reference formulation, Bristol- Myers Squibb company, USA) in Healthy Volunteers under Fed
      Conditions.

      Study Design: An Open-Label, Randomised, 2-Period, 2-Treatment, Crossover Study under fed
      condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Torrent's Metformin tablets 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucophage XR® of Bristol- Myers Squibb Company, USA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Torrent's Metformin tablets 500 mg</arm_group_label>
    <arm_group_label>Glucophage XR® of Bristol- Myers Squibb Company, USA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects who qualify for the study should meet the following inclusion criteria.

               1. Male subjects in the range of 18 - 45 years of age.

               2. Body weight within ± 15% of ideal weight as related to height and body frame
                  according to Life Insurance Corporation (LIC) Chart.

               3. Subjects with normal findings as determined by baseline history, physical
                  examination and vital signs (blood pressure, pulse rate, respiration rate and
                  body temperature)

               4. Subjects with normal findings as determined by hematological tests, serum
                  chemistry, urine analysis, ECG and X-ray.

               5. Willingness to follow the protocol requirement as evidenced by written, informed
                  consent.

               6. Agreeing to, not using any medication (prescription and over the counter),
                  including vitamins and minerals for two weeks prior to study &amp; during the course
                  of the study.

               7. No history or presence of significant alcoholism or drug abuse in the past one
                  year.

               8. Non-smokers, ex smokers and light smokers will be included. &quot; Light smokers are
                  defined as someone smoking 10 cigarettes or less per day, ex smokers as someone
                  who completely stopped smoking for at least 3 months.

        Exclusion Criteria:

          -  The subjects who qualify for the study should not meet the following exclusion
             criteria:

               1. Requiring medication for any ailment including enzyme-modifying drugs Use of any
                  drugs known to induce or inhibit hepatic drug metabolism (e.g.s, inducers:
                  barbiturates, carbazepine, phenytoin, glucocorticoids, omeprazole; inhibitors:
                  selective serotonin reuptake inhibitors (SSRIs), cimetidine, diltiazem,
                  macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones,
                  antihistamines) within 30 days prior to administration of the study medication.

               2. Any medical or surgical conditions, which might significantly interfere with the
                  functioning of gastrointestinal tract, blood-forming organs etc.

               3. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,
                  metabolic or psychiatric diseases.

               4. Participation in a clinical drug study or bioequivalence study 90 days prior to
                  present study.

               5. History of malignancy or other serious diseases.

               6. Refusal to abstain from food for ten (10) hours prior to study drug
                  administration on first day of each study period and for four (4) additional
                  hours each, post dose.

               7. Refusal to abstain from water for one hour pre dose and for two (2) hours, post
                  dosing.

               8. Any contraindication to blood sampling.

               9. Refusal to abstain from smoking or consumption of tobacco products 24 hours
                  before dosing until last sample collection of each period. Habituation of tobacco
                  necessitating uninterrupted tobacco consumption.

              10. Use of xanthine-containing beverages or food for 48 hours prior to each drug
                  dose.

              11. Blood donation 90 days prior to the commencement of the study.

              12. Subjects with positive HIV tests, HbsAg or Hepatitis-C tests.

              13. Known history of allergic reactions to Metformin or other related drugs.

              14. History of drug abuse in the past one year.

              15. Use of prescription medication or over the counter products (including natural
                  food supplements,vitamins, garlic as a supplement) within 2 weeks prior to
                  administration of study medication, except for topical products without systemic
                  absorption.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Torrent Research Centre</name>
      <address>
        <city>Bhat</city>
        <state>Gujarat</state>
        <zip>382 428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/</url>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>May 6, 2010</last_update_submitted>
  <last_update_submitted_qc>May 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2010</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

